Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Chengdu Zenitar Biomedical Technology / Equity Capital Markets

Chengdu Zenitar Biomedical Technology (CZBT HK)

<ul>
<li>Chengdu Zenitar, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. Jefferies and CICC are the joint sponsors.</li>
<li>In this note, we look at the company’s two late stage core products.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Chengdu Zenitar, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. Jefferies and CICC are the joint sponsors.
In this note, we look at the company’s two late stage core products.
We also look at the company’s pre-IPO investors and management team.


Chengdu Zenitar (赜灵生物) Pre-IPO: Meaningful Innovation with Best-In-Class Potential